Letter by Damman et al regarding articles, "Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)" and "American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)"

Circulation. 2012 Aug 28;126(9):e136-7; author reply e138. doi: 10.1161/CIRCULATIONAHA.112.102509.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Acute Coronary Syndrome / mortality*
  • Blood Platelets / drug effects*
  • Coronary Artery Bypass / mortality*
  • Death, Sudden, Cardiac / epidemiology*
  • Female
  • Humans
  • Male
  • Myocardial Infarction / mortality*
  • Myocardial Revascularization / mortality*
  • Piperazines / therapeutic use*
  • Randomized Controlled Trials as Topic*
  • Thiophenes / therapeutic use*
  • Thrombolytic Therapy / methods*

Substances

  • Piperazines
  • Thiophenes